RxDoctor Payments Data

Karen Swanson, DO

Pulmonary Disease · Scottsdale, AZNPI 1316911605

Payments from drug & device makers

What this record shows

9 manufacturers reported payments, led by Intuitive Surgical at 44.6% of the total. Reporting peaked in 2023 at $1,626 and has fallen 85.1% since, to $243 in 2025.

$3,601in general payments, 2019–2025

Across 37 payments — averaging $97.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Johnson & Johnson$723
  • Pulmonx Corporation$416
  • Actelion Pharmaceuticals US, Inc.$236
  • Covidien LP$208
  • Galvanize Therapeutics, Inc$130
  • plus $281 from 3 others
$169,739in research payments, 2019–2025

Across 18 payments — averaging $9429.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Johnson & Johnson$170K

What the payments were for

  • Travel & lodging$1,83451%
  • Food & beverage$1,76649%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,601 in reported general payments places this provider in the 55th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona

Medicare billing

Part B allowed, 2024
$122,545
Medicare patients
551
Services billed
1,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate48$630,453
OpsumitMacitentan36$441,964
AdempasRiociguat22$299,472
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$29,189
Breo ElliptaFluticasone/Vilanterol20$17,815
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$9,138
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,833
Tadalafil11$4,324
SymbicortBudesonide/Formoterol Fumarate13$4,192
Albuterol Sulfate HfaAlbuterol Sulfate18$489
Furosemide13$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$236$441,96436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 250 pulmonary disease providers in Arizona.

Other pulmonary disease in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →